Acetylcysteine in the treatment of severe COPD;Acetylcysteine in de behandeling van ernstige COPD

Nederlands Tijdschrift voor Geneeskunde

Volumn 150, Issue 22, 2006, Pages 1222-1226

  Dekhuijzen, P N R ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; CORTICOSTEROID DERIVATIVE; GLUTATHIONE; OXIDIZING AGENT; PLACEBO; TOXIC SUBSTANCE; SCAVENGER;

ARTICLE; CELL PROTECTION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORRELATION ANALYSIS; COUGHING; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; HOSPITAL READMISSION; HUMAN; INFLUENZA; KAPLAN MEIER METHOD; LUNG INJURY; LUNG PARENCHYMA; LUNG STRUCTURE; MAINTENANCE THERAPY; OXIDATIVE STRESS; SPUTUM VISCOSITY; LUNG FUNCTION TEST; REVIEW; TREATMENT OUTCOME;

ACETYLCYSTEINE; FREE RADICAL SCAVENGERS; HUMANS; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 33745756506     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet. 1997;349:1498-504.
2. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med. 1997;156(2 Pt 1):341-57.
3. Dekhuijzen PNR. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J. 2004;23:629-36.
4. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343:269-80.
5. Decramer M, Dekhuijzen PNR, Troosters T, Herwaarden C van, Rutten-van Molken M, Schayck CP van, et al. The Bronchitis randomized on NAC cost-utility study (BRONCUS): hypothesis and design. BRONCUS-trial Committee. Eur Respir J. 2001;17:329-36.
6. Decramer M, Rutten-van Molken M, Dekhuijzen PNR, Troosters T, Herwaarden C van, Pellegrino R, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis randomized on NAC cost-utility study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365:1552-60.
7. MacNee W, Rahman I. Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(5 Pt 2):S58-65.
8. Meyer A, Buhl R, Kampf S, Magnussen H. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am J Respir Crit Care Med. 1995;152:1055-60.
9. Mateos F, Brock JH, Perez-Arellano JL. Iron metabolism in the lower respiratory tract. Thorax. 1998;53:594-600.
10. Cantin AM, North SL, Hubbard RC, Crystal RG. Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol. 1987;63:152-7.
11. Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med. 1996:154(4 Pt 1):1055-60.
12. Maranzana A, Mehlhorn RJ. Loss of glutathione, ascorbate recycling, and free radical scavenging in human erythrocytes exposed to filtered cigarette smoke. Arch Biochem Biophys. 1998;350:169-82.
13. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989;6:593-7.
14. Moldeus P, Cotgreave IA, Berggren M. Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration. 1986;50(Suppl 1):31-42.
15. Tattersall AB, Bridgman KM, Huitson A. Acetylcysteine (Fabrol) in chronic bronchitis - a study in general practice. J Int Med Res. 1983;11:279-84.
16. Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study. Eur J Respir Dis Suppl. 1980;111:93-108.
17. Riise GC, Larsson S, Larsson P, Jeansson S, Andersson BA. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy? Eur Respir J. 1994;7:94-101.
18. De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J. 1997;10:1535-41.
19. Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J. 2000;16:253-62.
20. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther. 2000;22:209-21.
21. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ. 2001;322:1271-4.
22. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. N-acetyl-cysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J. 2003;21:795-8.
23. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med. 2001;163:1256-76.
24. Dekhuijzen PNR, Smeele IJM, Smorenburg SM. Richtlijn over niet-medicamenteuze behandeling bij COPD. Ned Tijdschr Geneeskd. 2006;150:1233-7.